Get the Stockscreener App
9.22
3.46%
-0.33
After Hours:
9.30
0.08
+0.87%
Rxsight Inc stock is traded at $9.22, with a volume of 492.35K.
It is down -3.46% in the last 24 hours and down -15.65% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$9.55
Open:
$9.53
24h Volume:
492.35K
Relative Volume:
0.59
Market Cap:
$379.10M
Revenue:
$128.29M
Net Income/Loss:
$-30.69M
P/E Ratio:
-11.24
EPS:
-0.82
Net Cash Flow:
$-27.17M
1W Performance:
-4.55%
1M Performance:
-15.65%
6M Performance:
+15.68%
1Y Performance:
-71.63%
1-Day Range:
$9.19
$9.6085
1-Week Range:
$9.19
$10.16
52-Week Range:
$6.32
$34.71
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
9.22 | 392.66M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
RxSight down on CFO transition - MSN
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
Precision Trading with Rxsight Inc. (RXST) Risk Zones - Stock Traders Daily
RxSight (NASDAQ:RXST) Trading Down 0.9%Time to Sell? - MarketBeat
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - yourwyominglink.com
Decliners Report: Is RxSight Inc a potential multi bagger2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
How Recent Developments Are Shaping The RxSight (RXST) Investment Story - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Expert Outlook: RxSight Through The Eyes Of 5 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight (RXST) soars 14.1%: Is further upside left in the stock? - MSN
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight stock price target raised to $11.50 from $11.00 at Jefferies By Investing.com - Investing.com South Africa
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com
RxSight Up 11% on Preliminary Q4, Full Year Results - ocbj.com
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference By Investing.com - Investing.com South Africa
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference - Investing.com Nigeria
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
RxSight (RXST) Reiterated at Neutral by UBS: 'Need More Regular Signs of Come-back' - StreetInsider
RxSight (RXST) Reiterated at Hold by Stifel Amid LAL, LDD Slowdown - StreetInsider
Benign Growth For RxSight, Inc. (NASDAQ:RXST) Underpins Stock's 30% Plummet - 富途牛牛
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
RxSight guides FY revenue above previous estimates, names new CFO - MSN
RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO - Nasdaq
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance - Investing.com
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer - manilatimes.net
RxSight, Inc. Reports Preliminary Financial Results for Q4 and Full-Year 2025; Announces Appointment of New CFO - Quiver Quantitative
RxSight says Mark Wilterding appointed as CFO effective Jan 11, 2026 - marketscreener.com
RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026 - TradingView — Track All Markets
RXSTRxsight, Inc. Latest Stock News & Market Updates - Stock Titan
RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026 - marketscreener.com
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely - Sahm
RxSight, Inc. (RXST) Investor Outlook: A Close Look At Its 7.98% Potential Upside - DirectorsTalk Interviews
Is RxSight Inc. stock dividend yield sustainableJuly 2025 Institutional & Stepwise Entry/Exit Trade Alerts - Улправда
Is RxSight Inc. stock trading at a premium valuation2025 Fundamental Recap & Real-Time Buy Signal Alerts - Улправда
Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - marketscreener.com
Will RxSight Inc. stock outperform international peers2026 world cup usa national team group stage playmakers possession football tactical prediction tactical review - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ... - bdtonline.com
Looking At The Narrative For RxSight (RXST) After A Better Than Feared Quarter - Yahoo Finance
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):